HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients ; day:18 ; month:6 ; year:2016 ; pages:1-13
Breast cancer research and treatment ; (18.6.2016), 1-13
- Creator
-
Kurozumi, Sasagu
- Contributor
-
Padilla, Mary
Kurosumi, Masafumi
Matsumoto, Hiroshi
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Ranger-Moore, Jim
Allred, D. Craig
Dennis, Eslie
Nitta, Hiroaki
SpringerLink (Online service)
- DOI
-
10.1007/s10549-016-3856-2
- URN
-
urn:nbn:de:1111-2016061911772
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
09.11.2025, 4:32 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kurozumi, Sasagu
- Padilla, Mary
- Kurosumi, Masafumi
- Matsumoto, Hiroshi
- Inoue, Kenichi
- Horiguchi, Jun
- Takeyoshi, Izumi
- Oyama, Tetsunari
- Ranger-Moore, Jim
- Allred, D. Craig
- Dennis, Eslie
- Nitta, Hiroaki
- SpringerLink (Online service)
Other Objects (12)
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy